Long-term effects of mepolizumab in patients with severe eosinophilic asthma: a 6-year real-life experience

HIGHLIGHTS

• What: The authors have shown that mepolizumab is able to significantly improve asthma control, reduce AER and eliminate or decrease the maintenance OCS dose within the first year of treatment and then maintain such achievements for the following 5 years. frontiersin.org 10.3389/fphar.2024.1449220 To the knowledge , this is the first study that involved patients followed without interruption for six whole years after treatment start. The authors explored both continuous and categorial variables to identify predictors of CR. This study has several strengths, since, to the knowledge , it is the first one that was . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.